Prevention of urolithiasis using febuxostat in patients with metabolic syndrome
- Authors: Protoshchak V.V.1, Paronnikov M.V.1, Babkin P.A.1, Sleptsov A.V.1
-
Affiliations:
- FGBVOU VO S. M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
- Issue: No 3 (2023)
- Pages: 13-20
- Section: Original Articles
- URL: https://journals.eco-vector.com/1728-2985/article/view/567994
- DOI: https://doi.org/10.18565/urology.2023.3.13-20
- ID: 567994
Cite item
Open Access
Access granted
Abstract
Introduction. Urolithiasis is a chronic highly recurrent disease. The development of new methods of its pathogenetic treatment and prevention is a priority task of practical urology.
Aim. To evaluate the clinical efficiency and safety of Febuxostat-SZ and to develop the rec-ommendations for its use in patients with uric acid stones.
Materials and methods. The analysis of 525 patients with urolithiasis was carried out. On the basis of a comprehensive examination, they were divided into two groups: in the group 1, pa-tients (n=231) had urolithiasis and metabolic syndrome, while in the group 2 (n=294), only urolithia-sis was diagnosed without metabolic syndrome. In both groups, depending on the stone composi-tion, in addition to general measures, specific stone prevention was carried out, which included die-tary regimen and drug therapy.
Results. Uric acid excretion after 6 months of therapy in patients with urolithiasis and meta-bolic syndrome decreased from 9.8±1.8 to 3.9±1.1 mmol/l, urinary excretion of citrates and urine acidity increased from 0.8 ±0.6 to 2.5±0.8 mmol/l and from 5.4±0.5 to 6.3±0.5, respectively, while serum uric acid level decreased from 451.4±15.1 up to 385.2±16.2 mmol/l. In the group of patients who, in addition to prescribing stone prevention, underwent correction of the metabolic syndrome, uric acid excretion after 3 months decreased by half: from 9.7±1.9 to 5.0±1.2 mmol/l, urine pH and citrate excretion increased from 5.4±0.4 to 6.3±0.5 and from 0.8±0.5 to 2.3±1.0 mmol/l, respective-ly, while serum uric acid level decreased from 459.5±17.7 to 370.9±15.1 mmol/l after 6 months of treatment.
Conclusion. The use of Febuxostat-SZ in the complex therapy of urinary stone disease showed high efficiency in normalizing urine acidity, the level of daily excretion and serum uric acid level, as well as satisfactory tolerability and a minimal profile of side effects.
Full Text
About the authors
V. V. Protoshchak
FGBVOU VO S. M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
Author for correspondence.
Email: protoshakurology@mail.ru
Ph.D., MD, professor, Chief of the Department and Clinic of Urology
Russian Federation, Saint PetersburgM. V. Paronnikov
FGBVOU VO S. M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
Email: paronnikov@mail.ru
Ph.D., MD, Head of the Urologic Department of Clinic of Urology
Russian Federation, Saint PetersburgP. A. Babkin
FGBVOU VO S. M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
Email: pavel.babkin@gmail.com
Ph.D., MD, professor, professor at the Department and Clinic of Urology
Russian Federation, Saint PetersburgA. V. Sleptsov
FGBVOU VO S. M. Kirov Military Medical Academy of the Ministry of Defense of Russian Federation
Email: slepzov_alive@mail.ru
urologist of Clinic of Urology
Russian Federation, Saint PetersburgReferences
- Curhan G., Goldfarb D.A.T. Epidemiology of Stone Disease. 2-nd International Consultation on Stone Disease. 2007;9:11–20.
- Lieske J.C., Pena de la Vega L.S.,et. al. Renal stone epidemiology in Rochester, Minnesota: an update. Kidney Int. 2006;69(4):760–764.
- Romero V., Akpinar H., Assimos D.G. Kidney stones: a global picture of pre- valence, incidence, and associated risk factors. Rev Urol. 2010;2(2–3)86–96.
- Scales C.D., Smith A.C., Hanley J.M., Saigal C.S. Prevalence of kidney stones in the United States. Eur Urol. 2012;62:160–165.
- Yasui T., Iguchi M., Suzuki S., Kohri K. Prevalence and epidemiological characteristics of urolithiasis in Japan: national trends between 1965 and 2005. Urology. 2008;71(2)209–213.
- Protoshchak V.V., Paronnikov M.V., Karpushchenko E.G. Medical and statistical characteristics of the incidence of urolithiasis in the Armed Forces. Russian military medical journal. 2020;341(11)11–18.
- Zabolevaemost’ naselenija Rossijskoj Federacii v 2013 godu: Statisticheskie materialy. M.; 2014. (jelektronnaja versija MZ RF i CNII organizacii i informatizacii zdravoohranenija MZ RF) Zabolevaemost’ naselenija Rossijskoj Federacii v 2013 godu (statisticheskij sbornik, 2014).
- Apolikhin O.I., Sivkov A.V., Moskaleva N.G., Solntseva T.V. Аnalysis of the uronephrological morbidity and mortality in the Russian Federation during the 10-year period (2002–2012) according to the official statistics. Experimental and Clinical Urology. 2014;(2)4–12.
- Kryukov E.V., Esipov A.V., Protoshchak V.V., et. al. Urolithiasis: organization of medical care in military medical institutions of central subordination. Russian military medical journal. 2022;343(2):19–25.
- Saigal C.S., Joyce G., Timilsina A.R. Urologic Diseases in America Project. Direct and indirect costs of nephrolithiasis in an employed population: opportunity for disease management? Kidney Int. 2005;68(4):1808–1814.
- Tiselius H.G. Who Forms Stones and Why? Eur Urol. Suppl European Association of Urology. 2011;10(5):408–414.
- Rule A.D., Lieske J.C., Li X. et al. The ROKS nomogram for predicting a second symptomatic stone episode. J Am Soc Nephrol. 2014;25(12):2878–2886.
- Ferraro P.M., Curhan G.C., D’Addessi A., Gambaro G. Risk of recurrence of idiopathic calcium kidney stones: analysis of data from the literature. J Nephrol. 2017;30(2):227–233.
- Dauw C.A., Yi Y., Bierlein M.J. et al. Medication Nonadherence and Effectiveness of Preventive Pharmacological Therapy for Kidney Stones. J Urol. 2016;195(3):648–652.
- Straub M., Strohmaier W.L., Berg W., et. al. Diagnosis and metaphylaxis of stone disease. World J. Urol. 2005;23(5):309–323.
- Tiselius H.G. How efficient is extracorporeal shockwave lithotripsy with modern lithotripters for removal of ureteral stones?. J. Endourol. 2008;22(2):249–255.
- Gajiyev N.K., Malkhasyan V.A., Mazurenko D.V., et. al. Urolithiasis and metabolic syndrome. The pathophysiology of stone formation. Experimental and Clinical Urology. 2018;(1):66–75.
- Rudenko V.I., Demidko Yu.L., Krayev G. Actual possibilities of pathogenetic treatment of patients with purine dismetabolism. Experimental and Clinical Urology. 2021;14(3):100–110.
- Wong Y., Cook P., Roderick P., Somani B.K. Metabolic Syndrome and Kidney Stone Disease: A Systematic Review of Literature. J Endourol. 2016;30(3):246–253.
- Golovanov S.A., Sivkov A.V., Anohin N.V., Drozhzheva V.V. Body mass index and chemical composition of urinary stones. Experimental and Clinical Urology. 2015;(4):94–99.
- Malkahasuan V.A., Semenyakin I.V., Kolontarev K.B. Metaphylaxis of urolithiasis: Educational and methodical allowance. M.: GBUZ «GKB name S.I. Spasokukockogo DMZ». 2021;76p.
- Shestaev A.Y., Paronnikov M.V., Protoshchak V.V., et al. A metaphylaxis oxalate urolithiasis in patients with metabolic syndrome. Experimental and Clinical Urology. 2014;3:53–56.
- Grjibovski A.M., Ivanov S.V., Gorbatova M.A. Descriptive statistics using Statistica and SPSS software. Science & Healthcare. 2016;1:7–23.
Supplementary files
